Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Neurocognition

In brief

Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).

Key facts

Study ID

NCT07651917

Run by

University of Zurich

People needed

50

Starts

2026-06-18

Expected to finish

2026-07-31

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Signed written consent
• Age >18
• Kyrgyz ethnicity
• Born, raised and living at approximately 2500 m
• Native or fluent in Russian language

You may not qualify if…

• Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.
• Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide
• Heavy smoking of >20 cigarettes per day
• Not able to read or adhere to the study protocol

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.